Likewise, Phillip and collaborators (2016) further reported that deficient-IGFBP2 glioma cell treatment with IGFBP2 resulted in a rapid increase of lysine-specific demethylase 1 (LSD1) and methylated histones that have been identified as direct targets of LSD1 (H3K9 and H3K27). The gene discussed is KDM1A; the disease is central nervous system cancer.